[3] 中国临床肿瘤学会, 2024 CSCO胃癌诊疗指南. [4] Cai T, Liang L, Zhao X, et al. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;193:104216. 审批...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. [12]van Mackelenbergh MT, Loibl S, Untch ...
1. Health Canada approves Keytruda as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. News release. Merck Canada. April...
乳腺癌是一种具有显著生物学特征和不同预后的异质性肿瘤,乳腺癌患者的治疗决策主要依赖于评估其肿瘤的激素受体(HR)和人表皮生长因子受体2(HER2)的表达状态。HER2阳性乳腺癌约占所有乳腺癌的20%-25%[1],这类乳腺癌更具侵袭性,患者预后较差。但是,以HER2为靶点的靶向治疗显著改善了HER2阳性乳腺癌患者预后。然而,随...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. ...
美国真实世界研究揭示HR低阳性、HR中/高阳性、HR阴性HER2阳性MBC的不同特征。在HER2阳性转移性乳腺癌（MBC）患者中，HR阳性与HR阴性肿瘤患者的治疗模式和临床结局存在差异。根据ASCO/CAP指南[1]，区分HR阳性和HR阴性肿瘤的免疫组织化学检测的现有标准阈值为≥1%，HR低阳性（1%-9%肿瘤细胞HR染色阳性）乳腺癌与传统的...
乳腺癌(BC)是美国女性中最常见的癌症,其生物学行为和临床特征具有高度异质性。当前,关于HER2低表达是否可以被确定为一个单独的亚型,目前尚存在争议,可能影响该人群的治疗决策和预后。近日,一项发表在Breast Cancer Research and Treatment的研...
[7] Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2...
The invention further relates to a kit of parts and to a pharmaceutical composition comprising a PARP inhibitor and an immune checkpoint inhibitor, preferably for use in a method of treating a breast cancer.GLAS, ANNUSKA MARIA
[6]Fasching, Peter A et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.Breast cancer research and treatmentvol. 175,3 (2019): 617-625.Johnston SRD, et al. ...